These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17109311)

  • 1. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care.
    Schackman BR; Merrill JO; McCarty D; Levi J; Lubinski C
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S247-53. PubMed ID: 17109311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial strategies for integrating buprenorphine into HIV care settings in the United States.
    Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence.
    Sullivan LE; Fiellin DA
    Clin Infect Dis; 2005 Sep; 41(6):891-6. PubMed ID: 16107991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine and HIV primary care: report of a forum for collaborative HIV research workshop.
    Miller V;
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S254-7. PubMed ID: 17109312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
    Turner BJ; Laine C; Lin YT; Lynch K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public policy statement on buprenorphine for opiate dependence and withdrawal.
    J Addict Dis; 2004; 23(4):116-7. PubMed ID: 15534969
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetic interactions between buprenorphine and antiretroviral medications.
    Bruce RD; McCance-Katz E; Kharasch ED; Moody DE; Morse GD
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S216-23. PubMed ID: 17109308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated program of buprenorphine in the primary care setting for HIV(+) persons in Rhode Island.
    Mitty J; Macleod C; Loewenthal H; Thompson L; Bazerman L
    Med Health R I; 2007 May; 90(5):145-7. PubMed ID: 17557657
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine use: the international experience.
    Carrieri MP; Amass L; Lucas GM; Vlahov D; Wodak A; Woody GE
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S197-215. PubMed ID: 17109307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing opioid addiction with buprenorphine.
    Donaher PA; Welsh C
    Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of opiate dependence in hands of primary care providers.
    Public Health Rep; 2003; 118(1):76. PubMed ID: 12622131
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of costs and utilization among buprenorphine and methadone patients.
    Barnett PG
    Addiction; 2009 Jun; 104(6):982-92. PubMed ID: 19466922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine and HIV primary care: new opportunities for integrated treatment.
    Khalsa J; Vocci F; Altice F; Fiellin D; Miller V
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S169-72. PubMed ID: 17109302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health services research: drug use and human immunodeficiency virus in the United States.
    Flanzer J
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S439-44. PubMed ID: 14648461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Models for integrating buprenorphine therapy into the primary HIV care setting.
    Basu S; Smith-Rohrberg D; Bruce RD; Altice FL
    Clin Infect Dis; 2006 Mar; 42(5):716-21. PubMed ID: 16447120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ryan White CARE Act Title IV programs: a preliminary characterization of benefits and costs.
    Abramowitz S; Greene D
    AIDS Public Policy J; 2005; 20(3-4):108-25. PubMed ID: 17624034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.